Location: Paris, France
Date: August 31 to September 4
European Society of Cardiology.
CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study
SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry
ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study
PURE: Impact of modifiable risk factors on cardiovascular disease and mortality
RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T
ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients
POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial
Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease
AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease
GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial
Salt substitution and community-wide reduction in blood pressure and hypertension incidence
HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study
SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study
MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation
DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial
CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention
RAPID‑TnT ‑ A randomised trial of a 1‑hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T
High-sensitivity troponin assays promise earlier discrimination of myocardial infarction. Yet, the benefits and harms of this improved discriminatory performance when incorporated within rapid testing protocols, with respect to subsequent testing and clinical events, has not been evaluated in an in-practice patient-level randomized study. This multicenter study evaluated the noninferiority of a 0/1-hour high-sensitivity cardiac troponin T protocol in comparison with a 0/3-hour masked hs-cTnT protocol in patients with suspected acute coronary syndrome presenting to the emergency department.
POPular Genetics - Genotype- guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infraction undergoing primary PCI: a randomized, open-label, multicenter trial
It is unknown whether patients undergoing primary percutaneous coronary intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors.
Long-term outcome of the Defibrillator After Primary Angioplasty Trial - Implantable Defibrillator Early After Primary Percutaneous Intervention for ST- Elevation Myocardial infraction
The DAPA trial showed that early ICD after primary PCI may be beneficial at improving long-term survival.
ENTRUST‑AF PCI ‑ Edoxaban‑based versus vitamin‑K‑ antagonist‑based anti‑thrombotic regimen following successful coronary stenting in atrial fibrillation patients
Prof. Andreas Goette speaks about the findings of ENTRUST-AF PCI trial.
Differences in the management and outcomes in congenital versus acquired heart disease
Julie De Backer speaks about the differences in the management and outcomes in congenital versus acquired heart disease.
ESC 2019 Congress Highlights
Prof. Silvia Giuliana Priori, the chair of the congress programme committee of the ESC congress 2019 highlights for us some of the key factors that really have made this meeting worthy.
Late Breaking Science in Cardiovascular Pharmacology
Prof. Bianca Rocca review the session about the new antithrombotic targets, what includes both antiplatelet and anticoagulant drugs.
The PURE study is the only large prospective international cohort study with substantial data from a large number of low-income countries, middle-income countries and high-income countries, using standardized and concurrent methods of sampling, measurement and follow-up.
The CLARIFY study
The study looked at 32,703 patients with CCS from 45 middle- to high-income countries enrolled in the prospective observational CLARIFY registry between November 2009 and June 2010. The primary outcome was cardiovascular death or nonfatal myocardial infarction over five years.
Controversies in secondary prevention: treating residual risk
Prof. Marja‑Riitta speaks about the debate session on secondary prevention, how to reduce residual risk.
ESC 2019 Guidelines
Prof. Robert Storey speaks about some of the updates in antiplatelet therapy and generally antithrombotic therapy in the management of patients with ischemic heart disease.
How wider use of combinations will improve control of the main cardiovascular risk factors
Prof. Claudio Borghi speaks about what we learned and how we can improve cardiovascular prevention.
Prof. Salim Yusuf speaks about what we learned and how we can improve cardiovascular prevention.
Lipid and Blood pressure lowering
Prof. Frank Ruschitzka speaks about lipid and blood pressure lowering regiments, about their most important prevention studies.
HOPE 4 ‑ Impact on cardiovascular risk of a community‑based multi‑faceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study
Cardiovascular disease is the leading cause of death throughout the world, with the majority of deaths occurring in low- and middle-income countries. Despite clear evidence for the benefits of blood pressure reduction and availability of safe and low-cost medications, most individuals are either unaware of their condition or not adequately treated.
Combinations of beta-blockers and angiotensin-converting enzyme inhibitors: what is the rationale?
Prof. Konstantinos Tsioufis speaks about the ombinations of beta-blockers and angiotensin-converting enzyme inhibitors.